AI Article Synopsis
- Pediatric Crohn's Disease treatment focuses on mucosal healing, growth optimization, and bone health, with Exclusive Enteral Nutrition (EEN) as the first-line therapy.
- Advances in understanding gut microbiota are revealing how EEN works, although strictly avoiding regular food during EEN is still crucial.
- The Crohn's Disease Exclusion Diet (CDED) offers a long-term treatment approach that minimizes EEN issues and supports remission by reducing harmful dietary components while using whole foods.
Article Abstract
The treatment of Pediatric Crohn's Disease (CD) requires attention both to achieve mucosal healing and to optimize growth, while also maintaining proper bone health. Exclusive Enteral Nutrition (EEN) is recommended as first-line treatment in luminal CD. The therapeutic mechanisms of EEN are being discovered by advances in the study of the gut microbiota. Although the total exclusion of a normal diet during the time of EEN continues to be of high importance, new modalities of dietary treatment suggest a successful future for the nutritional management of CD. In this sense, Crohn's Disease Exclusion Diet (CDED) is a long-term strategy, it apparently acts on the mechanisms that influence the appearance of inflammation (reducing dietary exposure to products negatively affecting the microbiota), but does so using specific available whole foods to achieve this goal, increases the time of clinical remission and promotes healthy lifestyle habits. The development of CDED, which partly minimizes the problems of EEN, has enabled a turnaround in the treatment of pediatric CD. This review highlights the role of enteral nutrition in the treatment of Crohn's disease with special emphasis on newer dietary modalities such as CDED.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7764146 | PMC |
| http://dx.doi.org/10.3390/nu12123793 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Effects of inflammatory bowel diseases on sexual function in women.
Ir J Med Sci
January 2025
Department of Urology, Başkent University Alanya Application and Research Center, Antalya, Türkiye.
Background: Inflammatory bowel disease (IBD) is a chronic disease that includes Crohn's disease and ulcerative colitis. Studies found that 40-60% of women diagnosed with IBD have sexual dysfunction (SD).
Aims: To determine SD and associated factors in women with IBD.
Telocytes in inflammatory bowel diseases: contributions to pathology and therapeutic potentials.
Front Cell Dev Biol
January 2025
Division of Gastroenterology and Hepatology, Department of Medicine, Penn State College of Medicine, Hershey, PA, United States.
Telocytes, a novel mesenchymal cell population, are characterized by their distinctive long and slender projections known as telopodes and have garnered significant interest since their formal introduction to the literature in 2010. These cells have been identified in various tissues, including the gastrointestinal (GI) tract, where they are suggested to play important roles in maintaining structural integrity, immune modulation, and barrier function. Inflammatory bowel diseases (IBD), which include Crohn's disease (CD) and ulcerative colitis (UC), are characterized by chronic inflammation and fibrosis.
View Article and Find Full Text PDFLaparoscopic intracorporeal anastomosis open anastomosis for ileostomy reversal in Crohn's disease: A single center retrospective study.
World J Gastrointest Surg
January 2025
Department of General Surgery, Chongqing General Hospital, Chongqing 401120, China.
Background: There is an increased maturation of laparoscopic intracorporeal anastomosis techniques. However, research on its application for small bowel stoma reversal in patients with Crohn's disease (CD) is limited. Therefore, in this study, we compared the perioperative outcomes between laparoscopic intracorporeal ileostomy reversal (LIIR) and open ileostomy reversal (OIR).
View Article and Find Full Text PDFDisseminated Chickenpox Following Live Varicella Vaccination in a Crohn's Disease Patient on Combination Immunosuppression.
Case Rep Gastrointest Med
January 2025
Department of Gastroenterology and Hepatology, Michigan Medicine, Ann Arbor, Michigan, USA.
Novel therapeutics used in the treatment of inflammatory bowel disease pose an increased risk of viral reactivation in patients. We present a case of a patient with refractory Crohn's disease (CD) who developed primary varicella (chickenpox) of a vaccine-viral strain after receiving combination immunosuppression with high-dose corticosteroids, tumor necrosis factor inhibitor (TNFi), and a Janus kinase inhibitor (JAKi) in the hospital. While this patient recovered and did not experience long term adverse effects, her case provides an opportunity for improvement.
View Article and Find Full Text PDFNeutrophils: From Inflammatory Bowel Disease to Colitis-Associated Colorectal Cancer.
J Inflamm Res
January 2025
Cancer Center, Daping Hospital, Army Medical University, Chongqing, People's Republic of China.
Inflammatory bowel disease (IBD) is a non-specific inflammatory disease of digestive tract, primarily manifesting as ulcerative colitis (UC) and Crohn's disease (CD). The precise etiology of IBD remains elusive. The interplay of genetic factors, environmental influences, and intestinal microbiota contributes to the establishment of an uncontrolled immune environment within the intestine, which can progressively lead to atypical hyperplasia and ultimately to malignancy over a long period.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!